Tradename: LANTIDRA
Proper Name: donislecel-jujn
Indication: Indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education.
Approval Date: 06/28/2023
Manufacturer: CellTrans Inc.
More: https://www.fda.gov/vaccines-blood-biologics/lantidra